Table 1.
Patient’s characteristics.
| N (%) | |
|---|---|
| Age | |
| 18–50 years | 160 (28.3) |
| 51–70 years | 299 (52.8) |
| >/= 71 years | 107 (18.9) |
| Patient sex | |
| Male | 249 (44.0) |
| Female | 317 (56.0) |
| Main diagnosis | |
| Hematological malignancies | 131 (23.1) |
| New diagnosis | 30 (5.3) |
| Chemotherapy (ongoing/completed <6 months) | 43 (7.6) |
| Anti-B cells/Anti-CD30/Anti-PD1/CAR-T | 45 (8.0) |
| Post transplant (auto/allo) | 13 (2.3) |
| Solid tumors | 191 (33.7) |
| Chemotherapy—adiuvant | 31 (5.5) |
| Chemotherapy—metastatic disease | 73 (12.9) |
| Immunotherapy—metastatic disease | 35 (6.2) |
| Target therapy—metastatic disease | 52 (9.2) |
| Immunorheumatological diseases | 86 (15.2) |
| ANCA associated vasculitis—immunodepressants agents | 44 (7.8) |
| ANCA associated vasculitis—Rituximab +/− steroids | 42 (7.4) |
| Neurological diseases | 158 (27.9) |
| Multiple Sclerosis | 58 (10.2) |
| Generalized Myastenia Gravis | 100 (17.7) |
| Vaccine | |
| mRNA-1237 Moderna | 105 (18.6) |
| BNT-162b2 Pfizer BioNTech | 461 (81.4) |
| All patients | 566 (100) |